Cleveland Clinic

EQS-News: Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Short course immune induction therapy, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Pharmaceutical industry, Pharmacovigilance

NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:

Key Points: 
  • NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:
    October 11-13: MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting.
  • The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Vaccine, Pharmacovigilance, Short course immune induction therapy

The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

Retrieved on: 
Tuesday, October 3, 2023
Blood pressure, Exercise, Cleveland Clinic, University, Pediatrics, ARS, Symantec Endpoint Protection, Clinical trial, NDA, VAS, American Academy, American Academy of Allergy, Asthma, and Immunology, Trial of the century, Committee, Asthma, Rhinitis, Literature, The Journal of Allergy and Clinical Immunology, Journal, Patient, Translational research, Anaphylaxis, Adrenaline, SAN, Irritation, Epinephrine autoinjector, HR, AAAAI, Cleveland, Heart rate, Caregiver, FDA, Safety, Complete Response Letter, Emax, Palladium, Pharmaceutical industry, Vaccine, SBP, PD, Allergy, Immunology, Medicine

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.

Key Points: 
  • JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.
  • The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.
  • For repeat doses of neffy, mean maximum changes in PD responses for both blood pressure and heart rate were statistically greater than repeat doses of EpiPen.
  • In addition, the PK profile for a second dose of neffy was approximately dose-proportional, unlike EpiPen, where the second dose delivered less incremental epinephrine exposure than the first dose.

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Retrieved on: 
Tuesday, October 3, 2023
Patent, Cleveland Clinic, Partnership, Cancer, National Cancer Institute, SAN, Menopause, Ovarian cancer, Pharmaceutical industry

SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa's novel ovarian cancer vaccine technology.

Key Points: 
  • SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa's novel ovarian cancer vaccine technology.
  • The patent, titled "Ovarian Cancer Vaccines", was invented by the late Dr. Vincent Tuohy of Cleveland Clinic and covers nucleic acid-based delivery of the vaccine.
  • Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.
  • Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are delighted to receive this patent from the USPTO as it broadens protection of our novel ovarian cancer vaccine technology.

Health Data Analytics Institute (HDAI) Announces $31 Million Funding Round to Scale Predictive Risk Platform

Retrieved on: 
Monday, October 2, 2023
Cleveland Clinic, Population health, Health, Case management (US healthcare system), EVP, Synthetic media, INVU (song), History, Acos, Patient, Physician, Machine learning, Generative, Artificial intelligence, AI, Chamoun, Scale, Dana–Farber Cancer Institute, Medical device, Houston Methodist Hospital

BOSTON, Oct. 2, 2023 /PRNewswire/ -- Health Data Analytics Institute (HDAI)— an artificial intelligence (AI) company focused on empowering clinicians, optimizing care pathways, and improving patient outcomes — today announced an oversubscribed Series C financing to scale its predictive risk platform.

Key Points: 
  • Several preeminent health systems including Houston Methodist, Cleveland Clinic, and Dana-Farber Cancer Institute, are collaborating with HDAI on various initiatives.
  • HDAI has additional collaborations with over 40 Medicare Accountable Care Organizations (ACOs) through which it collectively generates 50 million weekly predictions for one million patients.
  • The platform forecasts health risk at patient, practice, institution and/or regional levels and supports clinicians and institutions in driving performance improvements.
  • Health Data Analytics Institute (HDAI) is a care optimization, decision support and provider enablement company powered by big data, AI-powered analytics, expert insights and point of care technology solutions.

Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohs Micrographic Surgery, Cancer Journal Reports

Retrieved on: 
Monday, October 2, 2023
Columbia University, Contraindication, Columbia University Irving Medical Center, Cleveland Clinic, SCC, Radiation, Probability, University, Coagulopathy, Doctor of Philosophy, Skin, Anatomy, ASTRO, Mohs surgery, SRT, Skin cancer, Cancer, NMSC, MMS, BCC, Head, National Comprehensive Cancer Network, Toxicity, Research, Radiation therapy, Neck, SCCS, Medical Subject Headings, Dermatology, Incidence, Death, Patient, Treatment, University of South Florida College of Medicine, Carcinoma, American Society for Radiation Oncology, PubMed, European Society for Medical Oncology, Recurrence, Society, Medical imaging, Veterinary medicine, Dentistry, Pharmaceutical industry, Physician, Surgeon

BURR RIDGE, Ill., Oct. 2, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT, or IGSRT), today announced a newly published study revealing that IGSRT technology is superior to Mohs micrographic surgery (MMS). Image-Guided SRT is the most advanced nonsurgical treatment for common skin cancers. This peer-reviewed study "supports IGSRT as an effective treatment option for individuals with early stage NMSCs (nonmelanoma skin cancers)." The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.

Key Points: 
  • The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.
  • The report, entitled, "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery," appears in the journal Clinical and Translational Radiation Oncology , which is published by the European Society for Radiotherapy & Oncology (ESTRO).
  • Medical Subject Headings were used to search PubMed for reports of 2-year recurrence probability rates of NMSCs treated by MMS.
  • The authors observe that prior to the invention of Mohs surgery, superficial radiation therapy (SRT) was a standard therapy offered by dermatologists for nonmelanoma skin cancer.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Abstract, Cleveland Clinic, Lung transplantation, Liquid biopsy, Lung, Pleural disease, Patient, Annual general meeting, American College of Chest Physicians, Sightline (architecture), Pleural cavity, American College, Medical imaging, Lung cancer

The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.

Key Points: 
  • The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.
  • Lung EpiCheck is being developed using markers discovered in Nucleix’s proprietary EpiCheck® Lung Atlas.
  • The Lung Atlas is an early lung cancer detection discovery platform that was constructed and developed as part of a multi-institutional effort to map epigenetic and genetic changes associated with early-stage lung cancer, focusing on stage I disease.
  • Session Title: Late-Breaking Development in Lung Cancer, Lung Transplantation, and Pleural Disease
    The CHEST 2023 abstracts will be available on the journal CHEST website at: https://journal.chestnet.org/meetings .

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Retrieved on: 
Monday, October 2, 2023
Cognition, ASA, Abstract, Abstract (summary), BIO, Cleveland Clinic, Central nervous system, Atrium Health Wake Forest Baptist, Respiratory rate, Oxygen, Woman, Colectomy, Research, CNS, Șaeș, PCA, Patient, Hypoventilation, Disease, Heart rate, Cleveland, GI, Society, Morphine, Cryptocurrency, Pharmaceutical industry, Medical device, Trevena

CHESTERBROOK, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.

Key Points: 
  • The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting.
  • “We are pleased to announce completion of the initial analysis of respiratory data from the ~200 patient VOLITION study generated at Cleveland Clinic and Wake Forest Baptist Health,“ said Carrie Bourdow, President and CEO of Trevena.
  • “We are excited to present these new results at the upcoming ASA meeting in October.”
    VOLITION Study Data, Including Continuous Respiratory Monitoring Analysis, to be Presented at ASA in San Francisco from October 13-17, 2023.
  • VOLITION is a real-world, open-label, multi-site, post-approval clinical outcomes study in 203 adult patients undergoing major non-cardiac surgery (197 patients with evaluable respiratory data).

Mount Sinai Announces New System Chief of Genomic Medicine

Retrieved on: 
Tuesday, September 26, 2023
Genomic Health, Cleveland Clinic, University, Population health, Genetics, Icahn School of Medicine at Mount Sinai, Public, Yale New Haven Health System, Murray, Brigham and Women's Hospital, University college, Research, Department of Medicine – University of Pamplona, DSM-IV codes, Mount Sinai, Genetic distance, Doctor of Philosophy, Harvard Medical School, Publication, MD, American College of Medical Genetics and Genomics, Patient, Division, Internal medicine, Cancer, James D. Watson Institute of Genome Sciences, Clinical, Diagnosis, Hospital, Medical genetics, American College, Health, Mount Sinai Health System, Penn State University College of Medicine, Vaccine, Pharmaceutical industry, Medical device, Genomics, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai. He will lead its efforts to harness the power of genomic discovery to develop new ways to prevent and treat diseases, including cancers, heart problems, and genetic disorders.

Key Points: 
  • Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • Before joining the Mount Sinai Health System, he led cutting-edge efforts to integrate genomic medicine into clinical care delivery at Harvard Medical School, Geisinger Community Medical Center, and Yale New Haven Health System.
  • "With the investment that the Mount Sinai Health System has made in genetics and genomics technology in the clinical and research arenas, we are making an impact upon the care we provide to patients in a significant way," said Monica Kraft, MD, the Murray M. Rosenberg Professor of Medicine and System Chair of the Department of Medicine at Mount Sinai Health System and Icahn Mount Sinai.

Revolutionary Senior Care Platform Homecare Hub Sets Sights on Expansion, Secures Strategic Seed Funding from Inception Health, Ballad Ventures, CABHI, Blue Lion Global, AARP

Retrieved on: 
Tuesday, September 26, 2023
Cloud, Medicine, Housing, Investment, Long-term care, Dignity, Toronto-Dominion Bank, Hospital for Sick Children, Goldman Sachs, Hospital, Patient, Cleveland, Cleveland Clinic, University, Internal medicine, TD, Ageing, Froedtert Health, Organization, Dementia, Becker's Hospital Review, University of Waterloo, VC, Senior, AARP, Medical college, Uber, Baycrest Health Sciences, TD Bank Ballpark, Tufts Medical Center, IBM, Partnership, Ballad Health, Airbnb, Quality of life, Froedtert Hospital, Trillium Health Partners, Nursing

The oversubscribed $2.5 Million USD round exceeded initial targets, and additional milestone-based funding was also secured.

Key Points: 
  • The oversubscribed $2.5 Million USD round exceeded initial targets, and additional milestone-based funding was also secured.
  • "Homecare Hub is leading the way in closing the gaps for complex hospital discharges.
  • "With Homecare Hub, we're investing in the future of more personalized, high-quality, and affordable care options in both post-acute and long-term care.
  • The Blue Lion Global Fund participated and placed operating partner Matt Atkin to play a hands-on role on at Homecare Hub.